Pan-RAF inhibitors provide a new targeted treatment approach for BRAF-altered gliomas whilst not inducing the RAS-dependent paradoxical activation of the MAPK pathway, unlike the type I BRAF inhibitors (119, 120). The gene discussed is BRAF; the disease is central nervous system cancer.